uly 18, 2003
DOR BioPharma Enters Into Agreements For a Private Placement of $5.4 Million
Financing Led By Top Tier Biotechnology Investors
Lake Forest, IL – July 18, 2003, DOR BioPharma Inc. (AMEX: DOR) announced that it has entered into definitive agreements for the sale of securities in a private placement to selected institutional and accredited investors for gross proceeds of approximately $5.4 million.


July 7, 2003
DOR BioPharma Executes Exclusive Worldwide License Agreement For Injectable Rights To Ricin Vaccine Technology
Company Unveils Parallel Ricin Vaccine Development Programs
Lake Forest, IL – July 7, 2003, DOR BioPharma Inc. (AMEX: DOR) (“DOR”) announced it has executed an exclusive worldwide license agreement with the University of Texas Southwestern Medical Center at Dallas (UT Southwestern) to license issued U.S. patent and pending patent applications pertaining to all injectable uses of novel recombinant ricin A chain mutants as vaccines to protect against poisoning by ricin. In January, the Company announced an exclusive option agreement, which covers the development of nasal, pulmonary and oral ricin vaccines.


July 3, 2003
DOR BioPharma Appoints Geoff Green as Vice President of Clinical Operations
Newly Created Position to Spearhead orBec® Clinical Trial Program
Lake Forest, IL – July 3, 2003, DOR BioPharma Inc. (AMEX: DOR) (“DOR” or the “Company) announced today that Geoff Green has been appointed to the newly created position of Vice President of Clinical Operations and will join the Company later this month.


June 19, 2003
DOR BioPharma Will Advance orBec® To Phase II Trials For Irritable Bowel Syndrome
Decision To Pursue Second Indication Follows Positive Results In Animal Models
Lake Forest, IL - June 19, 2003, DOR BioPharma Inc. (AMEX: DOR) (the “Company” or “DOR”) announced that the Company’s lead product orBec® has demonstrated positive results in preliminary experiments with animal models of Irritable Bowel Syndrome (IBS)-like pain. Based on these positive findings, DOR is planning to conduct a Phase II clinical trial in patients who suffer from post-infection IBS.